Vanguard Global Advisers
NAUT icon

Vanguard Global Advisers’s Nautilus Biotechnolgy NAUT Stock Holding History

Vanguard Global Advisers’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.1K Hold
16,607
– – ﹤0.01% 3216
2026
Q1 		$64.4K Buy
+16,607
New +$40.8K ﹤0.01% 2909

Other funds holding NAUT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

Vanguard Global Advisers's NAUT Position: Q2 2026 in Review

Vanguard Global Advisers held its Nautilus Biotechnolgy (NAUT) position steady in Q2 2026 at 16,607 shares worth $31.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3216.

Vanguard Global Advisers first reported a position in NAUT in Q1 2026 and has held it in 2 quarters since. The position peaked at $64.4K in Q1 2026. 91 funds tracked by Wall St. Rank hold NAUT as of Q2 2026.

  • Vanguard Global Advisers held 16,607 shares of Nautilus Biotechnolgy worth $31.1K as of Q2 2026.
  • Vanguard Global Advisers left its Nautilus Biotechnolgy share count unchanged in Q2 2026.
  • Nautilus Biotechnolgy made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3216 holding.
  • Vanguard Global Advisers first reported a position in Nautilus Biotechnolgy in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Nautilus Biotechnolgy position peaked at $64.4K in Q1 2026.
  • 91 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.